Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study

Trial Profile

Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs IC 51 (Primary) ; Hepatitis A vaccine inactivated
  • Indications Encephalitis virus infections; Hepatitis A
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Intercell
  • Most Recent Events

    • 16 Jul 2009 Results published in the Vaccine journal.
    • 02 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top